{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:54:14Z","timestamp":1771606454611,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Qilu Pharmaceutical Co. Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This multicenter, open-label, single-arm trial (ClinicalTrials.gov, NCT05236621) was conducted to confirm the efficacy and safety of generic pomalidomide plus dexamethasone in Chinese patients with relapsed or refractory multiple myeloma (RRMM). Total 79 eligible RRMM patients were planned to be included. Patients were treated with generic pomalidomide (4\u00a0mg daily on days 1\u201321, orally) and low-dose dexamethasone (40\u00a0mg\/day on days 1, 8, 15, and 22, orally; 20\u00a0mg for patients aged\u2009&gt;\u200975\u00a0years) in 28-day cycles until disease progression with a maximum treatment duration of 2\u00a0years. The primary endpoint is the overall response rate (ORR) assessed by the independent review committee per the 2016 International Myeloma Working Group guidelines. A total of 85 eligible patients were included in this study from 32 centers in China, with a median age of 62.0 (range, 39\u201376) years, a median prior line of therapy of 4 (range, 1\u201316), and 41.2% patients with high-risk cytogenetics. The ORR was 38.8% (95% confidence interval (CI), 28.44\u201350.01). The disease control rate was 67.1% (95% CI, 56.02\u201376.87), meanwhile, the median progression-free survival was 5.55\u00a0months (95% CI, 3.68\u20137.52). Among the treatment-related adverse events (TRAEs), infective pneumonia (17.6%) was the most frequent non-hematologic adverse event, while a decrease in neutrophil count (52.9%) was the most common grade\u2009\u2265\u20093 TRAE. The study results indicated that the generic pomalidomide demonstrated consistent efficacy and a safety profile similar to the branded pomalidomide when combined with low-dose dexamethasone in Chinese RRMM patients.<\/jats:p><jats:p><jats:bold>Registration number<\/jats:bold> ClinicalTrials.gov NCT05236621, retrospectively registered on February 11, 2022.<\/jats:p>","DOI":"10.1007\/s00277-023-05558-y","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T10:02:26Z","timestamp":1702980146000},"page":"855-868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial"],"prefix":"10.1007","volume":"103","author":[{"given":"Huixing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aili","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinqiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuehong","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congmeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiwu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenqian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baijun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-8489","authenticated-orcid":false,"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"3","key":"5558_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"5558_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3389\/fonc.2019.01513","volume":"9","author":"S Wang","year":"2019","unstructured":"Wang S, Xu L, Feng J, Liu Y, Liu L, Wang J, Liu J, Huang X, Gao P, Lu J, Zhan S (2019) Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis. Front Oncol 9:1513. https:\/\/doi.org\/10.3389\/fonc.2019.01513","journal-title":"Front Oncol"},{"issue":"5","key":"5558_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/cm9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W (2022) Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 135(5):584\u2013590. https:\/\/doi.org\/10.1097\/cm9.0000000000002108","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"5558_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blade J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, International Myeloma Working G (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26(1):149\u2013157. https:\/\/doi.org\/10.1038\/leu.2011.196","journal-title":"Leukemia"},{"issue":"11","key":"5558_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/s1470-2045(13)70380-2","volume":"14","author":"JS Miguel","year":"2013","unstructured":"Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14(11):1055\u20131066. https:\/\/doi.org\/10.1016\/s1470-2045(13)70380-2","journal-title":"Lancet Oncol"},{"issue":"12","key":"5558_CR6","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC (2014) Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 123(12):1826\u20131832. https:\/\/doi.org\/10.1182\/blood-2013-11-538835","journal-title":"Blood"},{"issue":"10214","key":"5558_CR7","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/s0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Mac\u00e9 S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC (2019) Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394(10214):2096\u20132107. https:\/\/doi.org\/10.1016\/s0140-6736(19)32556-5","journal-title":"Lancet"},{"issue":"3","key":"5558_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/s1470-2045(22)00019-5","volume":"23","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC (2022) Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol 23(3):416\u2013427. https:\/\/doi.org\/10.1016\/s1470-2045(22)00019-5","journal-title":"Lancet Oncol"},{"key":"5558_CR9","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J (2022) Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol: Jco2102815. https:\/\/doi.org\/10.1200\/jco.21.02815","DOI":"10.1200\/jco.21.02815"},{"issue":"19","key":"5558_CR10","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J (2018) Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 379(19):1811\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa1805762","journal-title":"N Engl J Med"},{"issue":"6","key":"5558_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/s1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P (2021) Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 22(6):801\u2013812. https:\/\/doi.org\/10.1016\/s1470-2045(21)00128-5","journal-title":"Lancet Oncol"},{"issue":"6","key":"5558_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Mart\u00ednez-L\u00f3pez J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"5558_CR13","unstructured":"National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guideline on Multiple Myeloma. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1445. Accessed Sept 22 2023"},{"issue":"1","key":"5558_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"issue":"8","key":"5558_CR15","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"issue":"26","key":"5558_CR16","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/jco.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863\u20132869. https:\/\/doi.org\/10.1200\/jco.2015.61.2267","journal-title":"J Clin Oncol"},{"issue":"26","key":"5558_CR17","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","volume":"125","author":"K Sehgal","year":"2015","unstructured":"Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV (2015) Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 125(26):4042\u20134051. https:\/\/doi.org\/10.1182\/blood-2014-11-611426","journal-title":"Blood"},{"issue":"10","key":"5558_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3324\/haematol.2014.117077","volume":"100","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF (2015) Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica 100(10):1327\u20131333. https:\/\/doi.org\/10.3324\/haematol.2014.117077","journal-title":"Haematologica"},{"issue":"4","key":"5558_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","volume":"128","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Rollig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P (2016) Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood 128(4):497\u2013503. https:\/\/doi.org\/10.1182\/blood-2016-02-700872","journal-title":"Blood"},{"issue":"1","key":"5558_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/bjh.17499","volume":"194","author":"SJ Harrison","year":"2021","unstructured":"Harrison SJ, Perrot A, Alegre A, Simpson D, Wang MC, Spencer A, Delimpasi S, Hulin C, Sunami K, Facon T, Vlummens P, Yong K, Campana F, Inchausp\u00e9 M, Mac\u00e9 S, Risse ML, van de Velde H, Richardson P (2021) Subgroup analysis of ICARIA-MM study in relapsed\/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol 194(1):120\u2013131. https:\/\/doi.org\/10.1111\/bjh.17499","journal-title":"Br J Haematol"},{"issue":"1","key":"5558_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-023-00807-9","volume":"13","author":"B Puertas","year":"2023","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E, Escalante F, Rey-Bua B, Padilla I, Garc\u00eda-Sanz R, Puig N, Guti\u00e9rrez NC, Mateos MV (2023) Multiple myeloma with t(11;14): impact of novel agents on outcome. Blood Cancer J 13(1):40. https:\/\/doi.org\/10.1038\/s41408-023-00807-9","journal-title":"Blood Cancer J"},{"issue":"1","key":"5558_CR22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1186\/s12885-022-09802-y","volume":"22","author":"WJ Fu","year":"2022","unstructured":"Fu WJ, Wang YF, Zhao HG, Niu T, Fang BJ, Liao AJ, Bai H, Lu J (2022) Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial. BMC Cancer 22(1):722. https:\/\/doi.org\/10.1186\/s12885-022-09802-y","journal-title":"BMC Cancer"},{"issue":"9","key":"5558_CR23","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.26639","volume":"97","author":"E Kastritis","year":"2022","unstructured":"Kastritis E, Migkou M, Dalampira D, Gavriatopoulou M, Fotiou D, Roussou M, Kanellias N, Ntanasis-Stathopoulos I, Malandrakis P, Theodorakakou F, Sevastoudi A, Eleutherakis-Papaiakovou E, Triantafyllou T, Terpos E, Katodritou E, Dimopoulos MA (2022) Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. Am J Hematol 97(9):1142\u20131149. https:\/\/doi.org\/10.1002\/ajh.26639","journal-title":"Am J Hematol"},{"issue":"9","key":"5558_CR24","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/jco.21.01987","volume":"41","author":"R Lannes","year":"2023","unstructured":"Lannes R, Samur M, Perrot A, Mazzotti C, Divoux M, Cazaubiel T, Leleu X, Schavgoulidze A, Chretien ML, Manier S, Adiko D, Orsini-Piocelle F, Lifermann F, Brechignac S, Gastaud L, Bouscary D, Macro M, Cleynen A, Mohty M, Munshi N, Corre J, Avet-Loiseau H (2023) In multiple myeloma, high-risk secondary genetic events observed at relapse are present from diagnosis in tiny, undetectable subclonal populations. J Clin Oncol 41(9):1695\u20131702. https:\/\/doi.org\/10.1200\/jco.21.01987","journal-title":"J Clin Oncol"},{"key":"5558_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-016-0040-7","volume":"5","author":"T Ichinohe","year":"2015","unstructured":"Ichinohe T, Kuroda Y, Okamoto S, Matsue K, Iida S, Sunami K, Komeno T, Suzuki K, Ando K, Taniwaki M, Tobinai K, Chou T, Kaneko H, Iwasaki H, Uemura C, Tamakoshi H, Zaki MH, Doerr T, Hagiwara S (2015) A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. Exp Hematol Oncol 5:11. https:\/\/doi.org\/10.1186\/s40164-016-0040-7","journal-title":"Exp Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05558-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05558-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05558-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T10:05:08Z","timestamp":1707905108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05558-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["5558"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05558-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"10 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read the manuscript and made the decision to submit it for publication. The corresponding author had final responsibility for the decision to submit for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This trial was designed through collaboration between the investigators and Qilu Pharmaceutical Co., Ltd., the manufacturer of generic pomalidomide in Jinan, China. The study's design was a joint effort between the sponsor and the study committee. Wenming Chen, Juan Li, Huixing Zhou, Yafei Wang, Jiao Chen, Aili He, Jie Jin, Quanyi Lu, Ying Zhao, Junjun Li, Ming Hou, Liping Su, Xun Lai, Wei Wang, Lihong Liu, Yanping Ma, Da Gao, Wenhong Lai, Xin Zhou, Hongmei Jing, Jinqiao Zhang, Wei Yang, Xuehong Ran, Congmeng Lin, Jianping Hao, Taiwu Xiao, Zhenqian Huang, Zhigang Zhu, Qing Wang, Baijun Fang, Binghua Wang, Yanping Song, and Zhen Cai received research funding from Qilu Pharmaceutical Co. Ltd. Moreover, Bo Liu, Yanan Zhu, Xinai Yang, and Xiaoyan Kang were employees of Qilu Pharmaceutical Co. Ltd. All authors declare that they have no other competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}